Last €19.03 EUR
Change Today +0.89 / 4.91%
Volume 0.0
FEJ On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:45 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

auxilium pharmaceuticals inc (FEJ) Snapshot

Open
€18.87
Previous Close
€18.14
Day High
€19.03
Day Low
€18.87
52 Week High
02/28/14 - €23.15
52 Week Low
04/30/13 - €10.54
Market Cap
956.2M
Average Volume 10 Days
23.9
EPS TTM
--
Shares Outstanding
50.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AUXILIUM PHARMACEUTICALS INC (FEJ)

auxilium pharmaceuticals inc (FEJ) Related Bloomberg News

View More Bloomberg News

auxilium pharmaceuticals inc (FEJ) Related Businessweek News

No Related Businessweek News Found

auxilium pharmaceuticals inc (FEJ) Details

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, together with its subsidiaries, develops and markets pharmaceutical products for urology and sexual health worldwide. The company markets Testim, a testosterone gel for the topical treatment of hypogonadism; TESTOPEL, an implantable TRT product; Edex, a injectable drug for erectile dysfunction (ED); Osbon ErecAid, a device for treating ED; STENDRA, a line oral therapy for ED; Striant, a buccal system for testosterone delivery; and XIAFLEX for the treatment of Dupuytren's contracture in adults with a palpable cord, as well as for the treatment of Peyronie’s. It also markets Theo-24 for the treatment of COPD and asthma; and Semprex-D for the treatment of seasonal allergic rhinitis. In addition, the company is developing XIAFLEX, which is in Phase IIb clinical trial for the treatment of adhesive capsulitis, as well as in Phase IIa clinical trial for the treatment of edematous fibrosclerotic panniculopathy. Further, it is developing a high concentration testosterone gel product. The company sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors, and chain drug stores. It has a development and license agreement with BioSpecifics Technologies Corp.; development, commercialization, and supply agreement with Pfizer, Inc.; collaboration agreement with the Swedish Orphan Biovitrum AB; development, commercialization, and supply agreement with Asahi Kasei Pharma Corporation; and collaboration agreement with Actelion Pharmaceuticals Ltd. The company was founded in 1999 and is headquartered in Chesterbrook, Pennsylvania.

639 Employees
Last Reported Date: 02/28/14
Founded in 1999

auxilium pharmaceuticals inc (FEJ) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $666.2K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $383.9K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $437.1K
Chief Medical Officer
Total Annual Compensation: $394.7K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $363.9K
Compensation as of Fiscal Year 2013.

auxilium pharmaceuticals inc (FEJ) Key Developments

Auxilium and Swedish Orphan Announce Encore Presentation of Xiaflex/Xiapex Data At European Association of Urology Congress

Auxilium Pharmaceuticals Inc. and Swedish Orphan Biovitrum AB announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX(R)/Xiapex(R) (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These data were presented at the 29(th) Annual European Association of Urology (EAU) Congress being held April 11 -- 15, 2014 in Stockholm, Sweden. Poster presentations on XIAFLEX/Xiapex included encore analysis from the pivotal Phase 3 IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials which evaluated XIAFLEX for the treatment of PD. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy. Xiapex is approved by the EMA for the treatment of Dupuytren's contracture (DC), and as the Market Authorization Holder in Europe, Sobi intends to submit a Variation to the European Medicines Agency (EMA) to extend the Xiapex label to include Peyronie's disease. Highlights of the data related to the use of XIAFLEX/Xiapex in PD include: A post-hoc analysis of the pooled data from the IMPRESS I and II Phase 3 trials showed improved clinical outcomes following CCH-treatment regardless of subjects' baseline PD treatment history, erectile function scores, and/or prostatectomy history. The global safety analysis of seven clinical trials of CCH for the treatment of PD shows that the adverse events were mostly localized to the penis, non-serious and resolved without intervention before the next injection. Serious adverse events (SAEs) related to treatment were also all localized to the penis in these clinical studies. A total of 60 (5.7%) of CCH-treated subjects experienced at least one treatment-emergent SAE, nine of whom experienced treatment-related SAEs (five penile hematoma and four corporal rupture).

Auxilium Pharmaceuticals Inc. Proposes Amendment and Restatement of Certificate of Incorporation

Auxilium Pharmaceuticals Inc. announced that it will propose the amendment and restatement of the company's certificate of incorporation to increase the authorized common stock capital of the company from 120,000,000 to 150,000,000 shares at the annual meeting of stockholders to be held on May  21, 2014.

Swedish Orphan Biovitrum AB Becomes Market Authorisation Holder for Xiapex in Europe

Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals Inc. announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on 3 April, 2014. As the MAH, Sobi may now if it so elects, file for market authorisation for Xiapex for the treatment of Peyronie's disease and work is ongoing for that filing in the EU. Sobi holds the exclusive rights to commercialise Xiapex for the Dupuytren's contracture and Peyronie's disease indications, in these countries subject to applicable regulatory approvals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FEJ:GR €19.03 EUR +0.89

FEJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acrux Ltd A$1.68 AUD -0.005
Actavis plc $197.39 USD -1.99
Antares Pharma Inc $3.07 USD +0.03
Endo International PLC $57.26 USD -0.44
Mylan Inc/PA $46.92 USD -0.29
View Industry Companies
 

Industry Analysis

FEJ

Industry Average

Valuation FEJ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 5.2x
Price/Cash Flow 49.4x
TEV/Sales 1.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AUXILIUM PHARMACEUTICALS INC, please visit www.auxilium.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.